About Kindred Biosciences (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book2.81
Return on Equity-36.18%
Return on Assets-34.66%
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.
When will Kindred Biosciences make its next earnings announcement?
Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?
6 brokerages have issued 1-year price objectives for Kindred Biosciences' shares. Their predictions range from $8.00 to $11.00. On average, they anticipate Kindred Biosciences' share price to reach $9.90 in the next year. View Analyst Ratings for Kindred Biosciences.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Cytokinetics (CYTK), Atara Biotherapeutics (ATRA), Karyopharm Therapeutics (KPTI), Catalyst Pharmaceuticals (CPRX), Kura Oncology (KURA), Kala Pharmaceuticals (KALA), Jounce Therapeutics (JNCE), Seres Therapeutics (MCRB), Nantkwest (NK), Progenics Pharmaceuticals (PGNX), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), Aurinia Pharmaceuticals (AUPH), Achillion Pharmaceuticals (ACHN), Nightstar Therapeutics (NITE), Stemline Therapeutics (STML), CymaBay Therapeutics (CBAY) and ObsEva (OBSV).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Wendy Wee, Chief Financial Officer (Age 64)
- Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
- Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer (Age 63)
- Herbert D. Montgomery, Independent Director (Age 68)
- Raymond Townsend, Independent Director (Age 70)
- Ervin Veszpremi, Independent Director (Age 56)
Who owns Kindred Biosciences stock?
Kindred Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.82%), General American Investors Co. Inc. (2.39%), Wells Fargo & Company MN (1.20%), New York State Common Retirement Fund (0.95%), Pacific Grove Capital LP (0.67%) and Granite Investment Partners LLC (0.33%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?
Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?
Kindred Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Pacific Grove Capital LP, New York State Common Retirement Fund, Granahan Investment Management Inc. MA, SG Americas Securities LLC, Trexquant Investment LP, Bank of New York Mellon Corp and Prudential Financial Inc.. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario and Park West Asset Management Llc. View Insider Buying and Selling for Kindred Biosciences.
How do I buy Kindred Biosciences stock?
Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of Kindred Biosciences stock can currently be purchased for approximately $8.15.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $226.88 million. The biopharmaceutical company earns $-22,490,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Kindred Biosciences employs 41 workers across the globe.
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 Bayshore Hwy Ste 200, BURLINGAME, CA 94010-1617, United States. The biopharmaceutical company can be reached via phone at +1-650-7017901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (KIN)MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kindred Biosciences (NASDAQ:KIN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$9.50||$9.10||$9.00||$9.00|
|Price Target Upside: ||26.67% upside||23.81% upside||29.50% upside||29.50% upside|
Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History
Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History
(Data available from 12/17/2015 forward)
Kindred Biosciences (NASDAQ:KIN) Earnings History and Estimates Chart
Kindred Biosciences (NASDAQ KIN) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Kindred Biosciences (NASDAQ:KIN) Earnings Estimates
2017 EPS Consensus Estimate: ($0.29)
2018 EPS Consensus Estimate: ($1.38)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com
Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 66.85%
Kindred Biosciences (NASDAQ KIN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/12/2017||Park West Asset Management Llc||Major Shareholder||Buy||600,000||$7.50||$4,500,000.00|| |
|7/3/2017||Richard Chin||Insider||Sell||13,000||$8.26||$107,380.00|| |
|6/22/2017||Richard Chin||Insider||Sell||13,000||$7.75||$100,750.00|| |
|6/8/2017||Park West Asset Management Llc||Major Shareholder||Buy||15,311||$6.65||$101,818.15|| |
|5/11/2017||Park West Asset Management Llc||Major Shareholder||Buy||155,076||$6.83||$1,059,169.08|| |
|3/15/2017||Park West Asset Management Llc||Major Shareholder||Buy||400,000||$6.60||$2,640,000.00|| |
|3/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||4,200||$6.20||$26,040.00|| |
|3/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||18,066||$6.08||$109,841.28|| |
|1/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||1,690,000||$6.20||$10,478,000.00|| |
|1/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||131,500||$5.30||$696,950.00|| |
|1/6/2017||Park West Asset Management Llc||Major Shareholder||Buy||110,617||$5.10||$564,146.70|| |
|12/16/2016||Park West Asset Management Llc||Insider||Sell||18,000||$4.78||$86,040.00|| |
|12/14/2016||Park West Asset Management Llc||Major Shareholder||Buy||8,334||$4.75||$39,586.50|| |
|12/13/2016||Park West Asset Management Llc||Major Shareholder||Buy||1,148||$4.75||$5,453.00|| |
|12/12/2016||Park West Asset Management Llc||Major Shareholder||Buy||3,112||$4.74||$14,750.88|| |
|3/15/2016||Ernest Mario||Director||Buy||30,000||$3.55||$106,500.00|| |
|11/23/2015||Raymond Townsend||Director||Buy||2,000||$4.00||$8,000.00|| |
|11/18/2015||Raymond Townsend||Director||Buy||2,323||$4.78||$11,103.94|| |
|8/31/2015||Raymond Townsend||Director||Buy||1,677||$5.85||$9,810.45|| |
|8/14/2015||Raymond Townsend||Director||Buy||3,000||$6.04||$18,120.00|| |
|9/29/2014||Oleg Nodelman||Director||Buy||100,000||$9.56||$956,000.00|| |
|9/3/2014||Ernest Mario||Director||Buy||10,000||$10.55||$105,500.00|| |
|8/28/2014||Oleg Nodelman||Director||Buy||47,000||$10.85||$509,950.00|| |
|8/26/2014||Oleg Nodelman||Director||Buy||85,244||$10.50||$895,062.00|| |
|12/12/2013||Kevin Schultz||Insider||Buy||4,000||$7.00||$28,000.00|| |
|12/12/2013||Oleg Nodelman||Director||Buy||400,000||$7.00||$2,800,000.00|| |
|12/12/2013||Stephen Sundlof||SVP||Buy||1,000||$7.00||$7,000.00|| |
Kindred Biosciences (NASDAQ KIN) News Headlines
|Kindred Biosciences Inc (KIN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - December 11 at 9:52 PM
|Zacks: Analysts Expect Kindred Biosciences Inc (KIN) to Post -$0.33 EPS|
www.americanbankingnews.com - December 11 at 5:26 PM
|Kindred Biosciences (KIN) Given a $11.00 Price Target at B. Riley|
www.americanbankingnews.com - December 5 at 11:22 AM
|Kindred Biosciences (KIN) Given a $10.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - December 5 at 10:34 AM
|BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral|
www.reuters.com - December 4 at 11:57 AM
|KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses|
finance.yahoo.com - December 4 at 11:57 AM
|Kindred Biosciences (KIN) Rating Increased to Hold at ValuEngine|
www.americanbankingnews.com - December 3 at 9:36 AM
|Kindred Biosciences, Inc. (KIN) Expected to Earn FY2017 Earnings of ($1.16) Per Share|
www.americanbankingnews.com - November 22 at 6:22 AM
|B. Riley Begins Coverage on Kindred Biosciences, Inc. (KIN)|
www.americanbankingnews.com - November 20 at 7:40 AM
|Kindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC Wainwright|
www.americanbankingnews.com - November 18 at 11:38 AM
|Kindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - November 16 at 7:50 PM
|Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT|
finance.yahoo.com - November 13 at 11:02 AM
|Kindred Biosciences, Inc. (KIN) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 8 at 7:11 PM
|Kindred Biosciences Announces Third Quarter 2017 Financial Results|
www.bizjournals.com - November 8 at 11:27 AM
|Kindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per Share|
www.americanbankingnews.com - November 4 at 5:24 PM
|Kindred Biosciences, Inc. (KIN) Set to Announce Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 11:58 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - October 22 at 8:38 PM
|Kindred Biosciences to Announce Third Quarter 2017 Financial Results|
finance.yahoo.com - October 11 at 5:05 PM
|Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)|
www.americanbankingnews.com - October 6 at 4:10 PM
|Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference|
finance.yahoo.com - October 6 at 2:37 AM
|Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)|
www.americanbankingnews.com - October 1 at 2:32 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - September 27 at 8:44 PM
|Kindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow|
seekingalpha.com - September 27 at 4:17 PM
|Comparing Kindred Biosciences (KIN) and Its Peers|
www.americanbankingnews.com - September 20 at 8:08 AM
|Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof|
finance.yahoo.com - September 11 at 9:35 PM
|Kindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - September 2 at 8:46 PM
|Kindred Biosciences to Present at Upcoming Investor Conferences|
finance.yahoo.com - August 31 at 6:40 AM
|Kindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July|
www.americanbankingnews.com - August 14 at 3:04 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results|
www.americanbankingnews.com - August 8 at 11:14 AM
|Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT|
finance.yahoo.com - August 8 at 5:40 AM
|Kindred Biosciences Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 7 at 7:38 PM
|Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting|
finance.yahoo.com - August 4 at 11:59 PM
| Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - August 2 at 10:14 PM
|Kindred Biosciences, Inc. (KIN) Short Interest Update|
www.americanbankingnews.com - July 29 at 7:15 AM
|BRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing|
www.reuters.com - July 29 at 1:09 AM
|Kindred Biosciences to Announce Second Quarter 2017 Financial Results|
finance.yahoo.com - July 24 at 10:19 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 14 at 10:52 PM
|Park West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) Stock|
www.americanbankingnews.com - July 14 at 7:59 PM
|KindredBio Announces Pricing of Public Offering|
finance.yahoo.com - July 13 at 6:07 AM
|BRIEF-Kindredbio announces proposed public offering of common stock|
www.reuters.com - July 12 at 1:51 AM
|KindredBio Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - July 12 at 1:51 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - July 11 at 2:28 PM
|Former Boehringer Ingelheim manufacturing plant finds new owner|
www.bizjournals.com - July 7 at 6:46 AM
|Richard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) Stock|
www.americanbankingnews.com - July 6 at 8:06 PM
|Kindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for Zimeta|
www.streetinsider.com - June 26 at 8:03 PM
|BRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plant|
www.reuters.com - June 26 at 8:03 PM
|BRIEF-Kindred Biosciences announces Q1 loss per share $0.30|
www.reuters.com - May 4 at 1:16 AM
|Kindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides|
seekingalpha.com - May 4 at 1:16 AM
|Q4 2016 Kindred Biosciences Inc Earnings Release - After Market Close|
biz.yahoo.com - March 1 at 11:27 AM
|Kindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug Application|
www.streetinsider.com - February 6 at 11:19 PM
Kindred Biosciences (NASDAQ:KIN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement
Kindred Biosciences (NASDAQ KIN) Stock Chart for Sunday, December, 17, 2017